Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ALKS | US
-0.03
-0.10%
Healthcare
Biotechnology
30/06/2024
04/10/2024
28.97
28.67
29.06
28.49
Alkermes plc a biopharmaceutical company researches develops and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States Ireland and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence opioid dependence schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer. Its marketed products include ARISTADA an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence and LYBALVI an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V. Janssen Pharmaceutica Inc and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop commercialize and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin Ireland.
View LessPositive Momentum
Low 6-Month Volatility (<30%)
Low Market Beta (-0.4 to 0.8)
Low Debt to Asset (< 0.2)
Strong Operating Margin (> 25%)
High Short-term Volatility
Midcap (2B - 10B USD)
High Short percentage (> 15%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
34.6%1 month
33.2%3 months
33.6%6 months
29.6%12.07
12.80
3.53
0.29
0.17
10.31
2.67
-1.06K
354.93M
4.77B
4.77B
-
27.53
-61.70
-35.40
30.08
13.88
16.74
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
3.12
Range1M
3.42
Range3M
6.16
Rel. volume
0.64
Price X volume
32.57M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Krystal Biotech Inc | KRYS | Biotechnology | 177.11 | 5.09B | -0.15% | 44.85 | 0.92% |
Ultragenyx Pharmaceutical Inc | RARE | Biotechnology | 53.79 | 4.96B | -3.17% | n/a | 214.27% |
Corcept Therapeutics Incorporated | CORT | Biotechnology | 45.43 | 4.75B | -0.94% | 38.88 | 0.95% |
BridgeBio Pharma Inc | BBIO | Biotechnology | 25.23 | 4.74B | 0.60% | n/a | -158.23% |
ADMA Biologics Inc | ADMA | Biotechnology | 20.29 | 4.73B | 4.05% | 138.46 | 75.10% |
Madrigal Pharmaceuticals Inc | MDGL | Biotechnology | 208.41 | 4.53B | -0.35% | n/a | 13.77% |
Common Stock | IMVT | Biotechnology | 30.51 | 4.51B | 3.35% | n/a | 0.01% |
Biohaven Pharmaceutical Holding Company Ltd | BHVN | Biotechnology | 47.63 | 4.50B | -0.75% | n/a | 7.75% |
Crinetics Pharmaceuticals Inc | CRNX | Biotechnology | 53.14 | 4.25B | -1.63% | n/a | 6.42% |
Arcellx Inc. Common Stock | ACLX | Biotechnology | 78.23 | 4.21B | 2.62% | n/a | 15.25% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Polaris Industries Inc | PII | Recreational Vehicles | 82.25 | 4.59B | 0.61% | 14.90 | 170.51% |
Harley-Davidson Inc | HOG | Recreational Vehicles | 34.78 | 4.58B | -4.61% | 7.97 | 218.58% |
BRP Inc | DOOO | Recreational Vehicles | 59.31 | 4.30B | 2.21% | 24.84 | 552.13% |
LCI Industries | LCII | Recreational Vehicles | 118.67 | 3.02B | -1.21% | 25.17 | 77.66% |
VeriFone Systems Inc | PAY | Building Products & Equipment | 20.8 | 2.59B | 4.58% | 76.96 | 2.10% |
HNI Corporation | HNI | Building Products & Equipment | 53.27 | 2.51B | 0.72% | 21.28 | 76.47% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 10.31 | 0.76 | Expensive |
Ent. to Revenue | 2.67 | 3,674.48 | Cheaper |
PE Ratio | 12.07 | 38.01 | Cheaper |
Price to Book | 3.53 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 33.63 | 74.67 | Lower Risk |
Debt to Equity | 0.29 | -1.82 | Expensive |
Debt to Assets | 0.17 | 0.26 | Cheaper |
Market Cap | 4.77B | 3.73B | Market Leader |